Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYN-1601 for Pupil Dilation
NCT02946125Phase 2Completed
- Sponsor
- Hyperion DeFi
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of phenylephrine in Mydriasis (3 arms), sponsored by Hyperion DeFi. Primary endpoint: Pupil Dilation. Started Oct 2016; status: completed.
02
Drugs
phenylephrine
03
Conditions
Mydriasis
Beyond the preview
Go deeper on NCT02946125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946125.